AM-1714.

AM-1714 belongs to the class of the cannabilactones, tricyclic cannabinoids close to cannabinol whose pyran ring carries a 6-oxo group (lactone). The binding assays published in 2007 give a sub-nanomolar affinity for the CB2 receptor (Ki of 0.82 nM on mouse spleen membranes) against 400 nM for the CB1 receptor (rat brain synaptosomes), a selectivity of about 490-fold in favour of CB2; the in vitro assays of the study make the molecule a CB2 agonist. In a rat model of paclitaxel-induced neuropathy, the antiallodynic effect is blocked by the CB2 antagonist SR144528 but not by the CB1 antagonist SR141716, which is compatible with an action through the CB2 receptor (Rahn et al., 2008). AM-1714 has only a weak affinity for CB1, and its intrinsic efficacy at that receptor has not been characterised. The literature consulted stops there: no data on TRPV1, GPR55, PPARγ or 5-HT1A, no metabolism or toxicity study, and human data are entirely lacking.

Source

An entirely synthetic molecule, absent from cannabis and from any living organism. It was prepared in a university laboratory (Makriyannis team) as a ligand of high affinity and selectivity for the CB2 receptor, a target considered for cannabinergic molecules of therapeutic interest (Khanolkar et al., 2007). The sources consulted do not report it in any consumer product, and the molecule is not formulated for human use.

No biological pathway: the molecule derives from no plant or animal precursor. It belongs solely to synthetic chemistry, in the class of benzo[c]chromen-6-ones (cannabilactones).

European Union

The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It appears neither in the lists of the EUDA nor in those of UNODC recording the synthetic cannabinoids reported (Zangani et al., 2020). It does not appear in the schedules of the 1971 Convention on Psychotropic Substances (green list of the INCB, 35th and 36th editions).

France

AM-1714 is named in no entry of the consolidated ANSM list (updated 16 February 2026). It is not a tetrahydrocannabinol, nor an ester, ether or salt of tetrahydrocannabinol: the entry « Tétrahydrocannabinols, leurs esters, éthers, sels », placed in annex III since the decision of 6 February 2026, does not cover it. The generic family of annex IV introduced by the ANSM decisions of 22 May and 3 June 2024 (derivatives of the benzo[c]chromene nucleus) does, however, enumerate the substituents allowed at positions 1, 3, 6 and 9 (alkyl at 6 and at 9, for example); AM-1714 carries an oxo at 6 (lactone) and a hydroxyl at 9, which that enumeration does not mention. Its attachment to that family is therefore not established by the text: it is not listed by name, and the question of a classification by generic clause remains open. The absence of a nominative listing is neither an authorisation to sell nor a guarantee of safety, and the French lists are revised regularly.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

AM-1714 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Khanolkar AD et al., Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity, J Med Chem, 2007 (new tab)PMID 18038967
2. 2Rahn EJ et al., Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats, J Pharmacol Exp Ther, 2008 (new tab)PMID 18664590
3. 3Zangani C et al., The e-Psychonauts' 'Spiced' World: assessment of the synthetic cannabinoids' information available online, Curr Neuropharmacol, 2020 (AM-1714 present in NPSFinder, absent from the EUDA and UNODC lists) (new tab)PMID 32116194
4. 4ChEMBL, compound CHEMBL429797 (AM-1714): CB1 and CB2 binding data (new tab)
5. 5ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (annex III, tetrahydrocannabinols; annex IV, benzo[c]chromene derivatives family; AM-1714 not named) (new tab)
6. 6PubChem, compound record CID 9950486 (AM-1714) (new tab)

SMILES

CCCCCCC(C)(C)C1=CC2=C(C(=C1)O)C3=C(C=CC(=C3)O)C(=O)O2

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.